Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 1.00 |
| ▸ | DNM2 | P50570 | 3/20 | 0.58 |
| ▸ | GPR39 | O43194 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 7/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774715 | 0.81 | HRH4 (0.68) | HRH4DNM2GPR39CHEK1CHEK2 | |
| SCHEMBL1774600 | 0.80 | HRH4 (0.66) | HRH4DNM2GPR39CHEK1CHEK2 | |
| SCHEMBL4043020 | 0.78 | DNM2 (0.65) | HRH4DNM2CYP2C19MAP4K4CHEK1 | |
| SCHEMBL12497656 | 0.76 | DNM2 (0.62) | HRH4DNM2CYP2C19MAP4K4HRH3 | |
| SCHEMBL17581278 | 0.74 | DNM2 (0.60) | HRH4DNM2CYP2C19MAP4K4HRH3 | |
| SCHEMBL1774736 | 0.72 | HRH4 (0.56) | HRH4DNM2GPR39IKBKBCHEK1 | |
| SCHEMBL2580117 | 0.72 | HRH4 (0.56) | HRH4GPR39CHEK1CHEK2 | |
| SCHEMBL18985437 | 0.72 | HRH4 (0.56) | HRH4GPR39MAP4K4CHEK1CHEK2 | |
| SCHEMBL10187127 | 0.72 | HRH4 (0.56) | HRH4GPR39CHEK1CHEK2HRH3 | |
| SCHEMBL17300725 | 0.72 | DNM2 (0.57) | HRH4DNM2CYP2C19MAP4K4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885DNM2 3050/4885GPR39 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.